Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study.
Giannotta JA, Artoni A, Mancini I, Agosti P, Carpenedo M, Truma A, Miri S, Ferrari B, De Leo P, Salutari P, Mancini G, Molteni A, Rinaldi E, Bocchia M, Napolitano M, Prezioso L, Cuccaro A, Scarpa E, Condorelli A, Grimaldi D, Massaia M, Peyvandi F.
Giannotta JA, et al. Among authors: napolitano m.
J Thromb Haemost. 2024 Nov 14:S1538-7836(24)00686-X. doi: 10.1016/j.jtha.2024.10.034. Online ahead of print.
J Thromb Haemost. 2024.
PMID: 39549837
Free article.